Drug Discovery

Dewpoint Therapeutics launches with $60m Series A to advance proprietary platform for drugging condensates

Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched today with a $60 million Series A.

Lyndra Therapeutics raises $55m in Series B financing

Lyndra Therapeutics, which is moving toward making daily pills a thing of the past, has raised $55 million in Series B financing, funds it will use for Phase II clinical trials, expansion of its Phase I pipeline and manufacturing scale-up.

EIB to lend €100m to Orion for pharmaceutical research and development

Finnish pharmaceutical firm Orion Oyj has signed a loan agreement of €100m with the European Investment Bank in Espoo.

BridgeBio Pharma raises $299.2m in financing round

BridgeBio Pharma, a clinical-stage biopharmaceutical firm focused on the development of medicines for genetic diseases, has secured $299.2m funds to advanced its existing drug research and development programs.

GSK closes acquisition of Tesaro for $5.1bn

British drugmaker GlaxoSmithKline (GSK) has completed the acquisition of the US-based oncology-focused biopharmaceutical firm Tesaro for $5.1bn (£4bn).

Nash’s NASH NP-160 shows repeated positive results in second pre-clinical study

Nash Pharmaceuticals, a subsidiary of Breathtec Biomedical, has announced that its lead compound for non-alcoholic steatohepatitis (“NASH”) NP-160 showed repeated positive results in a recently completed study investigating its therapeutic effects in the widely used STAM mouse model from SMC Laboratories.

Kyn Therapeutics, Celgene partner on immuno-oncology therapies development

Kyn Therapeutics, a US-based clinical-stage biotech company, has entered into a global collaboration with biopharma major Celgene to develop immuno-oncology therapies.

Juvenescence closes first tranche of series B financing for further growth and development

Juvenescence, a biopharmaceutical company focused on modifying ageing and age-related disease, has closed the first tranche of its Series B financing, in the amount of $46m.

Sanofi to use Biomunex’s BiXAb platform to generate antibody therapeutics

Biomunex Pharmaceuticals has signed a licensing agreement with Sanofi for the development of bi-specific and multi-specific antibody therapeutics.